Search the Newsreel

Boston Scientific removes stroke prevention catheter after injury

Boston Scientific is removing certain catheters used for stroke prevention treatment due to a risk of the device tip separating during a procedure. The company has reported one injury related to this issue, which can lead to complications such as embolism, stroke, or the …

Boston Scientific Q2 2026 Earnings Preview

* Boston Scientific (BSX [https://seekingalpha.com/symbol/BSX]) is scheduled to announce Q2 earnings results on Wednesday, July 29th, before market open. * The consensus EPS Estimate is $0.83 [https://seekingalpha.com/symbol/BSX/earnings/estimates] (+10.7% Y/Y) and the consensus revenue estimate is $5.37B (+6.1% Y/Y). * Over the last 2 years, …

Boston Scientific Restructures Operations, Plans Workforce Cuts

Boston Scientific has announced a global restructuring plan approved on July 21, aiming for sustained cost efficiencies and continued growth, which will include headcount reductions. The company anticipates spending $700-800 million in pre-tax charges related to these efforts, which also involve supply chain optimization, …

Boston Scientific target price cut at UBS but remains a buy

UBS has lowered its price target for Boston Scientific (BSX) but maintains a "buy" rating. The firm believes that despite recent stock underperformance, growth will be driven by established business segments and new product launches.

Canaccord reiterates Boston Scientific stock rating after restructuring

Canaccord Genuity reiterated a Buy rating and a $70.00 price target for Boston Scientific (NYSE:BSX) after the company announced a global restructuring plan. This plan aims to optimize the supply chain, transfer production lines, and transform organizational structure, with an expected pre-tax expense reduction …

What To Expect From Boston Scientific’s (BSX) Q2 Earnings

What To Expect From Boston Scientific's (BSX) Q2 Earnings Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here's what to expect. Boston Scientific beat analysts' revenue expectations last quarter, reporting revenues of $5.20 billion, up 11.6% year on year. …

Boston Scientific Corp (BSX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Boston Scientific Corp (BSX), stating its current valuation score is 8.09, ranking 109 out of 199 in its industry. The company's P/E ratio is 18.93, significantly below its recent high but slightly above its recent low. The …

Boston Scientific Restructuring To Trim Workforce

(RTTNews) - Boston Scientific Corp (BSX) has unveiled a sweeping global restructuring program, according to its Form 8-K filing with the U.S. Securities and Exchange Commission. The plan, approved by the board of directors, is designed to streamline operations, optimize supply chains, and align …

Boston Scientific to restructure, cut costs by $500M annually

Boston Scientific Corp. is implementing a new 2026 Restructuring Plan to address challenges with key revenue drivers. This initiative is expected to lead to layoffs and aims to cut annual costs by $500 million. The company is responding to difficulties in its major financial …

Boston Scientific unveils new restructuring plan, expects job cuts

Boston Scientific's board has approved a new company-wide restructuring plan aimed at cutting costs and positioning the company for future growth. The plan, which involves supply chain optimization, production shifts, and organizational changes, is expected to result in some job losses while also involving …

Boston Scientific (NYSE: BSX) sets $700–$800 million restructuring with $500 million savings

Boston Scientific (NYSE: BSX) has approved a new global restructuring program, the 2026 Restructuring Plan, with estimated pre-tax charges of $700 million to $800 million. The plan aims to optimize the supply chain, transfer production lines, and reshape organizational structures to achieve sustained cost …

Boston Scientific Overturns $42M Patent Verdict

The U.S. Court of Appeals for the Federal Circuit has overturned a $42 million patent verdict against Boston Scientific, ruling that the patent involving drug-eluting stents was invalid. This decision is expected to positively impact Boston Scientific's stock price and enhance its competitive position …

Boston Scientific Gets $42 Million Stent Patent Verdict Reversed

The Federal Circuit has overturned a $42 million patent infringement verdict against Boston Scientific Corp. The ruling found that the patent held by the University of Texas related to medical devices, specifically drug-eluting stents, was invalid. A jury had previously determined Boston Scientific owed …

What Boston Scientific (BSX)'s Stronger-Than-Expected Segment Earnings Mean For Shareholders

What To Expect From Boston Scientific's (BSX) Q2 Earnings Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here's what to expect. Boston Scientific beat analysts' revenue expectations last quarter, reporting revenues of $5.20 billion, up 11.6% year on year. …

Boston Scientific Corp (BSX) Cash Flow

This article provides detailed cash flow statements for Boston Scientific Corp (BSX), covering quarterly and annual operating, investing, and financing activities. It includes historical data dating back to FY2012Q1, along with year-over-year percentage changes. The article also features an FAQ section explaining key cash …

BSX|Boston Scientific Corp|Kurs:51.165|Änderung %:+0.705

Boston Scientific Corp (BSX) Financial Health: Profitability & Balance Sheet Analysis

Boston Scientific Corp (BSX) currently holds a strong financial score of 8.02, ranking 46th out of 200 in the Healthcare Equipment & Supplies industry. The company exhibits stable financial health and high operating efficiency, with recent quarterly revenue increasing by 11.58% year-over-year and net …

Boston Scientific percutaneous catheters focus of FDA safety alert

[Nurse opening sterile package containing iv catheter in hospital setting] Carmen Ruiz alonso/iStock via Getty Images * The US FDA is recommending that certain lots of Boston Scientific's (BSX [https://seekingalpha.com/symbol/BSX]) ENROUTE Transcarotid Neuroprotection System percutaneous catheters be avoided following reports of arterial sheath tip …

Boston Scientific Corp (BSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Boston Scientific Corp's (BSX) revenue by business segment and geographical region. It shows that Interventional Cardiology Therapies and Electrophysiology are major contributors to its revenue, with a significant portion of its sales originating from the United States. …

Boston Scientific Corporation Revenue Breakdown – NYSE:BSX

Boston Scientific (BSX) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.83 per share, indicating an increase of 10.7% compared to the year-ago period. Analysts forecast revenues of $5.39 billion, representing an increase of 6.5% year over year. Over the last …

BSX|Boston Scientific Corp|Price:43.590|Chg%:+0.620

Boston Scientific Corp (BSX) is trading at $43.780, up 0.46%, with a market cap of $65.07B. The company exhibits strong fundamentals including high revenue and profit growth, and is considered fairly valued in the Healthcare Equipment & Supplies industry. While institutional ownership is very …

Boston Scientific stock trades firm as cardiovascular revenue grows and TAVR momentum supports earni

Boston Scientific's stock stability is driven by strong cardiovascular and MedSurg performance, with Q1 2025 net sales increasing by approximately 10% to $3.86 billion. The growth is particularly fueled by its Cardiovascular segment, which saw a 12% increase, largely due to demand for its …

Same Industry, Less Money: What Boston Scientific and ResMed Offers That Abbott Laboratories Does Not

This article analyzes the valuations of Abbott Laboratories (ABT), Boston Scientific (BSX), and ResMed (RMD) within the medical device industry. It highlights that ABT trades at a premium despite slower growth compared to BSX, which offers faster growth at a lower price. The author …

Boston Scientific (BSX) Enrolls First Patients In Global Faraflex AFib Trial

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment …

Boston Scientific stock trades steady as recent earnings and cardiovascular portfolio shape investor

Boston Scientific's stock performance is analyzed based on its recent earnings trajectory and its robust cardiovascular device portfolio. The company demonstrates strong organic revenue growth in its core segments and improved profitability, leading to significant EPS growth. Its strategy involves continuous innovation, strategic acquisitions, …

Boston Scientific, Stryker Settle Surgical Device Patent Dispute

Boston Scientific Corp. and Stryker Corporation have reached an agreement in principle to settle their patent dispute over a surgical device used to treat chronic lower back pain. This settlement comes shortly after Boston Scientific failed to block sales of Stryker’s competing product. The …

Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension …

Boston Scientific stock trades steadily as device maker grows revenue and prepares for next earnings

Boston Scientific (BSX) stock is trading steadily due to consistent share-price performance and revenue growth. The company, a major medical device manufacturer, is expanding its cardiovascular and neuromodulation portfolio and has reported strong double-digit revenue growth in recent periods, driven by product launches and …

Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and …

Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?

Boston Scientific BSX is slated to report second-quarter 2026 results on July 29, before the market opens. The Zacks Consensus Estimate for the company's second-quarter earnings per share (EPS) suggests 10.7% year-over-year growth to 83 cents. The estimate has remained constant in the past …

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

Boston Scientific (BSX) closed at $43.19 in the latest trading session, marking a -1.33% move from the prior day. This change lagged the S&P 500's daily gain of 0.89%. At the same time, the Dow added 0.74%, and the tech-heavy Nasdaq gained 1.29%. Shares …

Boston Scientific Corp. stock outperforms competitors despite losses on the day

Shares of Boston Scientific Corp. (BSX) fell 1.33% to $43.19 on Tuesday, marking its third consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) rose 0.89% and the Dow Jones Industrial Average (DJIA) …

Boston Scientific stock advances on strong sales and margin gains

Boston Scientific's stock is advancing due to strong sales and margin gains, highlighted by a 14.5% revenue growth to $4.1 billion and a 28.7% adjusted operating margin in its latest reported quarter. The company also demonstrated strong profitability with $1.3 billion in free cash …

What's Going On With Belo Sun Mining Corp. Stock Monday?

Boston Scientific to Combine Light Manufacturing, Global Distribution in Indiana Expansion

Boston Scientific is investing approximately $138 million in a new 500,000-square-foot facility in Plainfield, Indiana. This expansion will integrate light manufacturing with global medical device distribution, creating up to 300 jobs. The facility aims to enhance the company's logistics and production capabilities, serving as …